Skip to main content

Advertisement

Log in

Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background

Metastatic renal cell carcinoma (mRCC) has historically been refractory to cytotoxic and hormonal agents. IL-2 and IFN-α provide response in a minority of patients. Small molecule tyrosine kinase inhibitors and monoclonal antibodies have established a role in the setting of mRCC. However, there is a lack of data from the Indian subcontinent. The aim of this study was to look whether our patients behave similarly as reported in the Western data to targeted agents, especially sunitinib.

Methods

The study was a prospective observational study conducted for a period of 5 years from 2011 to 2016. Sixty-three patients received targeted agents and were recruited in the study. Five patients were excluded for various reasons, and three were lost to follow-up. Fifty-five patients were properly studied and followed up. Fifty patients received sunitinib, four patients received sorafenib, and one patient received parenteral temsirolimus. Patients were followed for AEs and survival.

Results

The most common AEs in patients taking sunitinib were fatigue (70 %), hand-foot syndrome (62 %), skin rash (58 %), mucosal inflammation (58 %), anorexia (42 %), skin discoloration (42 %), followed by dry mouth, dysgeusia, dyspepsia, dry skin, dry mouth, hair color changes, hypothyroidism, alopecia, oral pain/stomatitis, hypertension, decreased weight, photosensitivity, peripheral edema, erythema, and others. The median overall survival in our patients was 13.2 (95 % CI 10.1–16.5), progression-free survival was 8.1 months (95 % CI 6.4–10.5), and objective response was seen in 36 %.

Conclusion

Non-Western patients behave differently with sunitinib therapy compared to Western patients. Our patients have more mucocutaneous side effects and lesser overall survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Liu J, Mittendorf T, von der Schulenburg JM (2010) A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Invest 28:312–322

    Article  PubMed  Google Scholar 

  2. Gupta K, Miller JD, Li JZ et al (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34:193–205

    Article  PubMed  Google Scholar 

  3. Finley DS, Pantuck AJ, Belldegrun AS (2011) Tumor biology and prognostic factors in RCC. Oncologist 16:4–13

    Article  PubMed  PubMed Central  Google Scholar 

  4. Cella D (2011) Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. Oncologist 16:23–31

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hutson TE (2011) Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 16(Suppl 2):14–22. doi:10.1634/theoncologist.2011-S2-14

    Article  PubMed  PubMed Central  Google Scholar 

  6. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  7. Gore ME, Szczylik C, Porta C et al (2015) Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 113(1):12–19. doi:10.1038/bjc.2015.196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590. doi:10.1200/JCO.2008.20.1293

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rouffiac V, Bouquet C, Lassau N et al (2004) Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Invest Radiol 39:350–356

    Article  PubMed  Google Scholar 

  10. Robert C, Soria JC, Spatz A et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491–500

    Article  CAS  PubMed  Google Scholar 

  11. Pfizer Canada Inc (2006) SUTENT product monograph. Pfizer Inc., Canada

    Google Scholar 

  12. Rini BI, Schiller JH, Fruehauf JP et al (2008) Association of diastolic blood pressure (dBP) >90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J Clin Oncol 26(15 suppl):163s

    Google Scholar 

  13. Rautiola J, Donskov F, Peltola K (2016) Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. BJU Int 117(1):110–117

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are highly thankful to our radiology, biochemistry, and pathology departments for being immensely helpful in this study. We are highly thankful to the patients and their families who participated in this study. Although all of our patients in this study have reached their heavenly abode, all of them did put a great fight and have contributed their lives for cancer treatment.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Khalid Hamid Changal.

Ethics declarations

Conflict of interest

The authors have no conflicts of interests to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mir, M.H., Changal, K.H., Aziz, S.A. et al. Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?. Int Urol Nephrol 48, 1811–1816 (2016). https://doi.org/10.1007/s11255-016-1380-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-016-1380-2

Keywords

Navigation